NCT02502396View on ClinicalTrials.gov

Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center

CompletedOBSERVATIONAL
Enrollment

265

Participants

Timeline

Start Date

September 28, 2015

Primary Completion Date

March 15, 2022

Study Completion Date

March 15, 2022

Conditions
CancerDeep-vein Thrombosis of the Lower and Upper ExtremitiesPulmonary EmbolismNon-valvular Atrial Fibrillation
Interventions
OTHER

Retrospective Chart Review

Retrospective chart review study to evaluate Rivaroxaban's utilization in cancer patients for venous-thromboembolism (VTE) or non-valvular atrial fibrillation (NVAF). Study conducted from from January 1, 2012 to November 7, 2016 at MD Anderson Cancer Center in Houston, Texas.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT02502396 - Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center | Biotech Hunter | Biotech Hunter